Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:32 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,162 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Influenza vaccine Clear all

Conditions: Influenza
Interventions: Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine), LIQ001 (0.45mg), LIQ001 (1.8mg); Biological
Lead sponsor: Liquidia Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Melbourne, Florida

Conditions: Influenza A Subtype H5N1 Infection
Interventions: Seasonal Influenza Vaccine; Biological
Lead sponsor: Emory University; Other
Eligibility: Not listed
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Influenza
Interventions: Trivalent inactivated influenza vaccine; Biological
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 544 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Durham, North Carolina

Conditions: Lymphoma, Leukemia, Myelodysplastic Syndrome
Interventions: Fludarabine, Busulfan, Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 6 Months to 75 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Quality of Life, Injection Site Reaction, Adverse Drug Event, Systemic Reaction
Interventions: mRNA COVID-19, IIV4, Placebo (saline); Biological · Other
Lead sponsor: Duke University; Other
Eligibility: 5 Years and older
Enrollment: 348 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: Baltimore, Maryland • Durham, North Carolina • Cincinnati, Ohio

Conditions: 2009 H1N1 Influenza
Interventions: Live Attenuated H1N1 Influenza Vaccine, Influenza A (H1N1) 2009 Monovalent Vaccine, Influenza A (H1N1) 2009 Monovalent Vaccine/ Influenza A (H1N1) Monovalent Vaccine Live; Biological
Lead sponsor: University of Rochester; Other
Eligibility: 4 Years to 9 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Fever, Wheezing
Interventions: text message; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 2 Years to 11 Years
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 3
States / cities: Atlanta, Georgia • Boston, Massachusetts • New York, New York

Conditions: Moderate to Severe Asthma
Interventions: Tezepelumab, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 21 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 15
States / cities: Bakersfield, California • Huntington Beach, California • Miami, Florida + 12 more

Conditions: Influenza, Human
Interventions: 600 mg zanamivir + moxifloxacin placebo, 1200 mg zanamivir + moxifloxacin placebo, zanamivir placebo + moxifloxacin placebo, zanamivir placebo + 400 mg moxifloxacin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Influenza
Interventions: Influenza A/Vietnam/1203/2004 (H5N1; sanofi pasteur); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Influenza, COVID-19 (Coronavirus Disease 2019)
Interventions: Investigational Influenza Vaccine, Investigational COVID-19 Vaccine, Investigational Influenza and COVID-19 Combination Vaccine, Licensed Influenza Vaccine 1, Licensed Influenza Vaccine 2, Licensed Influenza Vaccine 3, Licensed COVID-19 Vaccine; Biological · Combination Product
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 2,650 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 31
States / cities: Anaheim, California • Lake Forest, California • Riverside, California + 26 more

Conditions: Influenza
Interventions: Trivalent inactivated influenza vaccine, Trivalent Baculovirus-expressed Influenza HA vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Influenza
Interventions: Influenza virus vaccine (Fluviral), Saline placebo; Biological
Lead sponsor: ID Biomedical Corporation, Quebec; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 7,400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 43
States / cities: Sacramento, California • San Francisco, California • Denver, Colorado + 34 more

Conditions: Influenza
Interventions: Peramivir, Placebo Comparator; Drug
Lead sponsor: BioCryst Pharmaceuticals; Industry
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 96
States / cities: Birmingham, Alabama • Hot Springs, Arkansas • Jonesboro, Arkansas + 93 more

Conditions: Novel Influenza A, H1N1, Influenza
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 894 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 86
States / cities: Anchorage, Alaska • Phoenix, Arizona • Little Rock, Arkansas + 52 more

Conditions: Respiratory Syncytial Virus
Interventions: Placebo, mRNA-1345, Fluzone HD; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 65 Years and older
Enrollment: 1,900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 34
States / cities: Scottsdale, Arizona • Dublin, California • Riverside, California + 29 more

Conditions: HIV, Cancer
Interventions: Fluzone High Dose Vaccine, Fluzone Standard Dose Vaccine; Biological
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 3 Years to 21 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Healthy
Interventions: Choice of TIV or FluMist with baseline advertisement, Choice of TIV or FluMist with enhanced advertisement and incentives, Control - Usual care offering TIV only with baseline advertisement; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years and older
Enrollment: 4,411 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 47
States / cities: Chatsworth, California • Novato, California • Sacramento, California + 34 more

Conditions: Diabetes
Interventions: Diabetes Digital Intervention, Generic Digital Intervention; Behavioral
Lead sponsor: Evidation Health; Industry
Eligibility: 18 Years and older
Enrollment: 94,321 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: San Mateo, California

Conditions: Influenza
Interventions: Non-invasive diagnostic testing; Other
Lead sponsor: Response Biomedical Corp.; Industry
Eligibility: Not listed
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 4
States / cities: Chicago, Illinois • St Louis, Missouri • Winston-Salem, North Carolina + 1 more

Conditions: Immune Response to Influenza Vaccine, Influenza A Virus Infection, Influenza B Virus Infection
Interventions: LAIV, IIV; Biological
Lead sponsor: Marshfield Clinic Research Foundation; Other
Eligibility: 5 Years to 17 Years
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Marshfield, Wisconsin

Conditions: Influenza
Interventions: Live Attenuated Influenza Vaccine; Drug
Lead sponsor: National Center for Occupational Health and Infection Control; Federal
Eligibility: 20 Years to 49 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Influenza, Human
Interventions: Blood sample, Nasal swab, Oropharyngeal swab, Stool sample, Symptom checklist; Other
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Influenza
Interventions: DNA vaccine, TIV; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 131 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 4
States / cities: Decatur, Georgia • St Louis, Missouri • Cincinnati, Ohio + 1 more

Search by objective public record fields.

A Study Evaluating the Safety and Tolerability of a Seasonal Influenza Vaccine Containing LIQ001

Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response

Feasibility of Cocooning Immunization Strategy With Influenza Vaccine

Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers

Simultaneous mRNA COVID-19 and IIV4 Vaccination Study

Effect of Age and Prior Immunity on Response to H1N1 Vaccines in Children

Fever and Wheezing Events in Children After US Influenza Vaccines Using Text Messaging

Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma

A Study to Evaluate the Effect of Intravenous Zanamivir on Cardiac Conduction in Healthy Volunteers

Revaccination With Subunit Influenza A/Vietnam/1203/2004 (H5N1) Vaccine

A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People

Trivalent Baculovirus-expressed Influenza HA Vaccine in Adults With Non-Hodgkin's B-cell Lymphoma

Study of the Protective Effect of an Injectable Influenza Vaccine Against Influenza Illness in Adults Under 50 y.o.

A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza.

Novel Influenza A (H1N1) Surveillance Registry

A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age

Immunogenicity of Fluzone HD,A High Dose Influenza Vaccine, In Children With Cancer or HIV

Assessing Choice in the Employer Setting (ACES) Study

Influenza Vaccination Digital Interventions for People Living With Diabetes

FLU A+B Nasal Swab Clinical Study

Randomized Study of Immune Response to Licensed Influenza Vaccines in Children and Adolescents

Evaluating Immune Response to Seasonal FluMist in Healthy Adults

A Pilot Study of Influenza Viruses Isolated From Immunocompromised Children and Adolescents

Seasonal Influenza DNA Vaccine Prime With Trivalent Inactivated Vaccine (TIV) Boost Compared to TIV Alone